Skip to content
Catalyst

PapersPMID:37181363

The clinical efficacy of melatonin in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in medicine2023The record ↗

  1. Finding, moderate evidenceno difference foundErythrocyte sedimentation rate

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “No statistically significant effects were revealed between the groups regarding changes in ESR (MD −0.12, 95% CI −0.64 to 0.39, p = 0.64; I2 0%, p for heterogeneity = 0.67) and NLR (MD 7.31, 95% CI −15.21 to 29.84, p = 0.52; I2 87%, p for heterogeneity < 0.01) after melatonin administration.”
    Study
    meta-analysis
    Effect
    −0.12 mean difference, 95% CI −0.64 to 0.39
    Population
    hospitalized adults with COVID-19 receiving melatonin plus standard care versus control (predominantly standard care alone, two trials placebo-controlled)

Study record

Design
meta-analysis
Species
human
Population
718 hospitalized (mostly) adult COVID-19 patients across 9 RCTs; melatonin plus standard care vs control (predominantly standard care alone, two trials placebo-controlled)
Participants
718
Comparator
placebo
Duration
not reported
Endpoints measured
9